Manou Overstijns

Dr. Manou Overstijns

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
MOManou Overstijns
Manou Overstijns
ARAmir El Rahal
Amir El Rahal
JGJohannes Goldberg
Johannes Goldberg
RRRoland Rölz
Roland Rölz
ARAndreas Raabe
Andreas Raabe
CFChristian Fung
Christian Fung
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) is well studied. Yet, little is known about the trend of aSAH severity. This systematic review aims to analyze the distribution of aSAH severity over time. We performed a systematic review of the literature according to the PRISMA-P guidelines. We included studies from January 1968 up to December 2022. Studies were included if they either reported the severity of aSAH as single increments of the corresponding 5-point scale or as a binary measure (good grade 1-3, poor grade 4-5) on the Hunt and Hess (HH) or World Federation of Neurosurgical Societies (WFNS) scale. Studies with fewer than 50 patients, (systematic) reviews, and studies including non-aSAH patients were excluded. A total of 2465 publications were identified, of which 214 met the inclusion and exclusion criteria. In total, 102,845 patients with an aSAH were included. Over the last five decades the number of good-grade HH (0.741 fold, p = 0.004) and WFNS (0.749 fold, p < 0.001) has decreased. Vice versa, an increase in number of poor grade HH (2.427 fold, p = 0.004), WFNS (2.289 fold, p < 0.001), as well as HH grade 5 (6.737 fold, p = 0.010), WFNS grade 4 (1.235 fold, p = 0.008) and WFNS grade 5 (8.322 fold, p = 0.031) was observed. This systematic review shows a worldwide 2-3 fold increase of poor grade aSAH patients and an 6-8 fold increase of grade 5 patients, over the last 50 years. Whether this evolution is due to more severe hemorrhage, improvements in neuro-intensive care and prehospital management, or to a change in grading behavior is unknown. This study strongly emphasizes the necessity for an improved grading system to differentiate grade 4 and grade 5 patients for meaningful clinical decision- making.

3 July 2025 in Brain and Spine
Verified
Journal Article
Open access
MOManou Overstijns
Manou Overstijns
ARAmir El Rahal
Amir El Rahal
KWKatharina Wolf
Katharina Wolf
NLNiklas Lützen
Niklas Lützen
UWUrs Würtemberger
Urs Würtemberger
FVFlorian Volz
Florian Volz
There is no accepted algorithm for the management of chronic subdural hematoma (cSDH) caused by spinal CSF leaks in spontaneous intracranial hypotension (SIH). This study analyses characteristics of cSDH in SIH to establish a practicable management algorithm. This retrospective cohort study included all patients with spinal CSF leak closure from April 2018 to April 2024. Demographics, leak type, treatment modalities, as well as cSDH characteristics, prevalence, and risk factors were analyzed. Among 272 SIH patients, 85 (31 %) concomitantly had cSDH, predominantly bilateral (88 %). Hematoma width ranged from 2 to 30 mm. cSDH prevalence was highest in CSF-venous fistulas (43 %), followed by ventral (31 %) and lateral leaks (22 %). Male sex (OR = 4; p < 0.001) and age >70 years (OR = 6; p = 0.008) were significant risk factors. Surgical evacuation was performed in 23 patients, with symptoms attributable to cSDH in 17/23 patients. The biggest cSDH without surgical treatment was 20 mm. No neurological deterioration occurred during diagnostics or treatment of CSF leaks. After leak closure, no cSDH, regardless of initial size or previous treatment, required additional treatment, and no recurrence occurred in the 3-month follow-up. Primary localization and targeted treatment of the spinal leak is safe in asymptomatic patients and cSDH ≤10 mm (“leak first” strategy). Immediate evacuation of the cSDH is mandatory in symptomatic patients (“subdural first” strategy). We consider the CSF leak closure as a causal treatment for cSDH resulting in a markedly low, close to zero, recurrence rate. Prospective validation of these findings is needed.

29 September 2025 in Neurosurgery
Verified
Journal Article
Closed access
MOManou Overstijns
Manou Overstijns
ICIstván Csók
István Csók
MBMarco Bissolo
Marco Bissolo
CSChristian Scheiwe
Christian Scheiwe
PRPeter Reinacher
Peter Reinacher
RRRoland Roelz
Roland Roelz
BACKGROUND AND OBJECTIVES: Chronic shunt-dependent hydrocephalus (CSH) is a common and serious complication after aneurysmal subarachnoid hemorrhage (aSAH). Active blood clearance and delayed cerebral ischemia prevention (ABCD) therapy, using intrathecal urokinase and nimodipine irrigation, aims to enhance blood clearance and prevent vasospasm. This study evaluates whether ABCD therapy reduces the incidence of CSH in aSAH patients. METHODS: A matched-pairs analysis was performed and 160 aSAH patients who had received ABCD therapy were compared with 160 controls. Patients were paired on the basis of a best fit model including the World Federation of Neurological Surgeons grade, age, cerebral herniation, intracerebral hemorrhage, and the initial Hijdra score. Patients were stratified by Hijdra score to account for blood load. The incidence of CSH was compared between groups using χ 2 tests, whereas a multivariable cause-specific Cox proportional hazards model was used to assess time to shunt-dependent hydrocephalus. In addition, multivariate logistic regression was performed to identify predictors of hydrocephalus. RESULTS: The incidence of CSH was significantly lower in the ABCD group (19.4%) compared with the standard care group (31.3%, P = .015). Subgroup analysis revealed that patients with the highest blood load (Hijdra 30-42) experienced a significant reduction in hydrocephalus (45.8% vs 22.5%, P = .026). By contrast, no significant effects were observed in patients with lower Hijdra scores. Multivariate analysis confirmed that the Hijdra score was a significant predictor of CSH in the standard care group ( P = .008) but not in the ABCD-treated group ( P = .843). CONCLUSION: aSAH patients selected for ABCD therapy had a significantly lower incidence of shunt-dependent hydrocephalus compared with matching controls. ABCD therapy may be an important preventive strategy in patients with severe subarachnoid hemorrhage.

29 September 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MOManou Overstijns
Manou Overstijns
SNSameer Nazeeruddin
Sameer Nazeeruddin
PSPierre Scheffler
Pierre Scheffler
RRRoland Roelz
Roland Roelz
JBJürgen Beck
Jürgen Beck
ARAmir El Rahal
Amir El Rahal
Objectives: The increasing incidence of unruptured intracranial aneurysms (UIAs) has led to significant demands on neurovascular boards. Large language models (LLMs), such as ChatGPT-4, ChatGPT-3.5, Claude, and Atlas GPT, have emerged as tools to support clinical decision-making. This study compares treatment recommendations from these AI models with those of an interdisciplinary neurovascular board to evaluate their accuracy and alignment. Methods: We retrospectively included all 57 patients with UIAs discussed by the neurovascular board in 2023. The board’s consensus decision served as the reference standard. Key clinical and radiographic data, including PHASES, ELAPSS, and UIATS scores, were provided to the AI models. Each model was tasked with recommending either conservative or operative management and specifying the treatment modality (clipping, coiling, flow diverter, or WEB device/flow diverter) where appropriate. AI model recommendations were compared with the board’s decisions for management and the specific treatment modality of the UIA. Results: ChatGPT-4 achieved the highest accuracy in correctly predicting conservative or operative management (89%) and specific treatment types (73%), followed by Atlas GPT (74% accuracy in conservative/operative decisions and 55% accuracy in specific treatment types), Claude (70% accuracy in conservative/operative decisions and 50% accuracy in specific treatment types), and ChatGPT-3.5 (82% accuracy in conservative/operative decisions and 27% accuracy in specific treatment types). ChatGPT-3.5 displayed a strong preference for clipping (94.3%). ELAPSS scores significantly influenced AI recommendations and decision-making, particularly for ChatGPT-4 and ChatGPT-3.5. Follow-up recommendations for conservative management were shorter among AI models, with Claude suggesting the shortest interval (7.72 months) compared to the neurovascular board’s 13.36 months. Conclusions: AI models, particularly ChatGPT-4, align closely with expert neurovascular board decisions and offer promising support for initial clinical decision-making, particularly in resource-limited settings. However, interdisciplinary neurovascular boards remain unreplaceable for UIA management, and AI should be viewed as a complementary tool. The observed improvement from ChatGPT-3.5 to ChatGPT-4 underscores the rapid evolution of AI technology, and further advancements are expected to enhance both performance and accuracy in the future.

21 April 2025 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
MOManou Overstijns
Manou Overstijns
PSPierre Scheffler
Pierre Scheffler
JBJürgen Buttler
Jürgen Buttler
JBJürgen Beck
Jürgen Beck
ARAmir El Rahal
Amir El Rahal
Procalcitonin (PCT) is a biomarker for bacterial infections, with controversial utility in diagnosing hospital-acquired pneumonia (HAP) in neurosurgical intensive care unit (NICU) patients. Establishing an optimal PCT cutoff value could enhance diagnostic accuracy. This retrospective single-center study included NICU patients hospitalized between January 1, 2021, and December 31, 2022, who underwent routine serum PCT measurement. HAP was diagnosed based on clinical, biochemical, microbiological, and radiological data. The optimal PCT cutoff value was identified using the Youden Index. Associations between PCT levels, radiological findings, sputum cultures, and confirmed HAP were analyzed using chi-square tests. A multivariate logistic regression was performed to identify independent predictors of elevated PCT. Among 2363 patients, 193 met inclusion criteria, and 148 were diagnosed with HAP. The optimal PCT cutoff value was 0.095 ng/mL, yielding a sensitivity of 89.2% and specificity of 93.3% ( p < 0.001). This cutoff resulted in a positive likelihood ratio of 13.3 and a negative likelihood ratio of 0.116. Radiological signs of pneumonia and positive sputum cultures were observed in 48.4% and 78.4% of HAP cases, respectively, but neither showed a significant association with HAP ( p = 0.135 and p = 0.056). Leukocytosis was significantly associated with HAP but had low specificity, while CRP showed a non-significant trend. In multivariate analysis, only confirmed HAP independently predicted PCT elevation. PCT, with a cutoff value of 0.095 ng/mL, shows high diagnostic accuracy for HAP in NICU patients and could enhance early identification and treatment. Our findings suggest that elevated PCT is primarily driven by HAP rather than non-infectious inflammatory triggers such as trauma or recent surgery. Further prospective studies are warranted to validate these findings.

12 October 2026 in Neurosurgery
Verified
Journal Article
Closed access
MOManou Overstijns
Manou Overstijns
Christian ScheiweChristian Scheiwe
Christian Scheiwe
ARAmir El Rahal
Amir El Rahal
PFPanagiotis Fistouris
Panagiotis Fistouris
RDRoberto Doria-Medina
Roberto Doria-Medina
RRRoland Roelz
Roland Roelz
BACKGROUND AND OBJECTIVES: Aneurysmal subarachnoid hemorrhage (aSAH) remains associated with high morbidity and mortality, largely determined by delayed cerebral ischemia (DCI). Active blood clearance and vasodilation (ABCD) therapy targets key pathophysiological mechanisms of DCI by enhancing the clearance of blood from cerebrospinal fluid and counteracts vasospasm through continuous intrathecal fibrinolytic and spasmolytic irrigation. Although ABCD therapy has previously been implemented using technically demanding treatment approaches, this study introduces ventriculolumbar irrigation (VLI) as a simplified, bedside-applicable method. This study evaluates whether VLI-based ABCD therapy is associated with an improvement in DCI and morbidity. METHODS: In this prospective registry study, consecutive aSAH patients treated with the novel VLI-based ABCD therapy (pressure-controlled VLI with urokinase and on-demand nimodipine) between 2019 and 2025 were compared with matched controls receiving standard care. The primary outcome was the incidence of DCI and the secondary outcome was modified Rankin Scale (mRS) at 180 days. RESULTS: Seventy-two patients treated with VLI-based ABCD therapy were compared with 144 matched controls. VLI treatment was associated with significantly lower rates of DCI (9.7% vs 29.9%, P < .001), morbidity (mean mRS 2.33 vs 3.37, P < .001), and shunt-dependent hydrocephalus (9.7% vs 31.9%, P < .001). Compared with isolated, passive cerebrospinal fluid drainage, VLI was associated with lower DCI rates (9.7% vs 30.7%, P < .001) and reduced morbidity (mean mRS 2.33 vs 3.39, P < .001). CONCLUSION: The novel and simplified VLI therapy was associated with considerably improved outcomes: lower DCI rates and shunt-dependent hydrocephalus. VLI offers a bedside technique to actively remove intrathecal blood and deliver intrathecal spasmolysis for the prevention of DCI. Randomized trials are needed to confirm these findings.